#التخصصي ينجح في تطبيق العلاج الجيني لمريض مصاب بفقر الدم المنجلي، عبر تعديل الخلايا الجذعية المكوِّنة للدم لتصحيح الخلل الوراثي المسبب للمرض، ثم إعادة حقنها في جسم المريض، ضمن دراسة سريرية تهدف إلى توسيع الخيارات العلاجية المتاحة للحالات غير المؤهلة للخضوع لزراعة خلايا جذعية من متبرعين.
للمزيد من المعلومات: https://t.co/FNTdZH8M2L
Genuinely excited to be finally able to fully share the first major output from the MEASURE consortium at #ASH25#ASH2025 - the largest cohort of paired tumor and remission WGS from patients with AML https://t.co/2WozDIrEtA
🚨 This is it people … you heard it first at #ASH25 🚨
ELN #MRD 205 guidelines are in press in @BloodPortfolio
Bad news: It’s more complicated than before… 🤯
Good news: there’s an app for it 😉
https://t.co/S0p6gDIQmk
This retrospective single-center study evaluates high-dose melphalan followed by busulfan/fludarabine conditioning in elderly patients with active #AML. Three-year overall survival was 44% and 40% of patients remained relapse-free. https://t.co/0jNuBchDXw
نجح #التخصصي بالرياض في علاج أول مريضة باستخدام الخلايا التائية المعدلة وراثياً، والمصنّعة محلياً، وذلك ضمن المرحلة الأولى من بحث سريري يستهدف مرضى سرطان الدم الليمفاوي الحاد المقاوم، في إنجاز نوعي يسهم في توطين العلاجات الجينية والخلوية بالمملكة.
لمزيد من المعلومات: https://t.co/EQV5pYbHtP
The effects of graft cryopreservation on patient outcomes in allogeneic HCT remain unclear. This UK study of cryopreserved vs. fresh allogeneic HCT found no statistically significant difference in overall survival at 12-month follow-up. For more: https://t.co/NWTq6pmwFk
Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction: a case series | Communications
@NatureMedicine @KFSHRC @KFSHRC_Research
The 1st case series...
Proud of our team https://t.co/8oC6tobGco
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia https://t.co/YRlQ3N7OW6
70 cases of B-cell #ALL with lineage switch after immunotherapy (anti-CD19) to AML or mixed phenotypic leukemia.
Dismal outcome with median OS 4.9 months.
#leusm @BloodPortfolio
https://t.co/1xKA5q1i1H
Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias: highlights from #EHA2025#EHA25
I can't understand e.g. if the stem cell lab refused to release the specifications of cellular therapy product e.g. CD34, TNC,etc...
Where is the quality?
#Novartis more practical in the this issue
🚨NEW - In vivo CAR T cell generation to treat cancer and autoimmune disease @capstantx direct delivery of mRNA-encoded CARs to CD8+ T cells in mouse & NHP models shows tumor control not only in blood, but also tissue. Immune reset seen at B cell recovery https://t.co/8TunddD8Vp